EUVIMEDEUVIMED entdecken
Vergleichsstudie

Treatment Outcomes in Patients with Carcinoma In Situ of the Larynx

Ahmed I Ghanem iD, Marissa Gilbert, Chun-Hui Lin, Christian E Keller iD, Glendon M Gardner, Ross Mayerhoff iD, Farzan Siddiqui

The Laryngoscope · 2025

DOI: 10.1002/lary.31786 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Laryngoscope, 2025. Verfasst von Ahmed I Ghanem und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Henry Ford Health-Cancer, Detroit, Michigan, U.S.A. Hauptthemen laut MEDLINE: Laryngeal Neoplasms, Carcinoma in Situ. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare survival endpoints in patients with laryngeal carcinoma in situ (L‐CIS) who received definitive radiotherapy (RT) versus other modalities as first‐line treatment and after disease recurrence.

Methods

This is a retrospective study of patients with L‐CIS treated between June 2001 and December 2021. Survival outcomes (recurrence‐free (RFS), invasion‐free (IFS), laryngectomy‐free (LFS), and overall survival (OS)) were compared between patients who had first‐line RT versus non‐RT modalities and for patients with recurrent disease who underwent second‐line RT.

Results

A total of 85 patients with L‐CIS were included (73 men [85.9%] and 12 [14.1%] women, median age of 65 [IQR: 55–74] years). Of these, 42 had first‐line RT (49.4%) and 43 (50.6%) had non‐RT treatment. After median follow‐up of 4.8 (IQR: 2.8–9) years, patients in the first‐line RT group had improved 2‐year (94.2% [95% confidence interval (CI): 86.7–100] versus 41.7% [CI: 29.3–59.5]) and 5‐year (90.6% [CI: 80.9–100] versus 27.5% [CI: 16.4–48.2]) RFS relative to non‐RT recipients ( p < 0.001). OS and IFS were similar between groups. However, patients in the RT group had worse 2‐year (94% [CI: 87–100] versus 98% [CI: 93–100]) and 5‐year (82% [CI: 68–99] versus 98% [CI: 93–100]; p = 0.013) LFS. All 35 patients with recurrent L‐CIS were successfully cured with second‐line treatments (12 received RT [34.3%]), and no differences in any survival endpoints were seen in these patients based on first‐line and second‐line treatments.

Conclusion

Although first‐line RT for L‐CIS led to improved recurrence‐free survival compared with other modalities, second‐line RT may be a particularly valuable option for recurrent CIS. Level of Evidence 3 Laryngoscope , 135:779–786, 2025

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Laryngeal NeoplasmsCarcinoma in SituHumansMaleFemaleMiddle AgedRetrospective StudiesAgedTreatment OutcomeNeoplasm Recurrence, LocalLaryngectomyLarynx

Stichwörter der Autor:innen

definitive radiation therapylaryngeal carcinoma in sitularyngeal preservationprogression to invasive laryngeal carcinomasevere laryngeal dysplasia

Autor:innen und Institutionen

  • Department of Radiation Oncology, Henry Ford Health-Cancer, Detroit, Michigan, U.S.A.
  • Clinical Oncology Department, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
  • Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan, U.S.A.
  • Department of Pathology and Laboratory Medicine, Henry Ford Health, Detroit, Michigan, U.S.A.
  • Department of Otolaryngology-Head and Neck Surgery, Henry Ford Health, Detroit, Michigan, U.S.A.

ORCID-Profile: Ahmed I Ghanem, Christian E Keller, Ross Mayerhoff

Zitieren

APA

I Ghanem, A., Gilbert, M., Lin, C. H., Keller, C. E., Gardner, G. M., Mayerhoff, R., & Siddiqui, F. (2025). Treatment Outcomes in Patients with Carcinoma In Situ of the Larynx. The Laryngoscope. https://doi.org/10.1002/lary.31786

Vancouver

I Ghanem A, Gilbert M, Lin CH, Keller CE, Gardner GM, Mayerhoff R, et al. Treatment Outcomes in Patients with Carcinoma In Situ of the Larynx. The Laryngoscope. 2025. doi:10.1002/lary.31786

BibTeX
@article{IGhanem2025,
  author = {I Ghanem, Ahmed and Gilbert, Marissa and Lin, Chun-Hui and Keller, Christian E and Gardner, Glendon M and Mayerhoff, Ross and Siddiqui, Farzan},
  title = {Treatment Outcomes in Patients with Carcinoma In Situ of the Larynx},
  journal = {The Laryngoscope},
  year = {2025},
  doi = {10.1002/lary.31786}
}
Kostenlos starten →